Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clin Oncol (R Coll Radiol). 2019 Aug;31(8):560-569. doi: 10.1016/j.clon.2019.06.002.
Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC.
肝细胞癌（HCC）是一种常见的恶性肿瘤，尽管其病因在东西方之间存在显著差异。大约一半的 HCC 病例在诊断时已处于晚期不可切除的 HCC，导致预后更差。在过去的 20 年中，晚期不可切除 HCC 的治疗模式已从完全姑息治疗转变为多学科治疗，由于新的和改进的局部、区域和全身治疗选择的出现，以及东西方的共同贡献，不断重新评估和可能重复治疗。应根据每个患者确定个体化的治疗计划，因为不同患者和不同患者群体对相同治疗的决策和治疗反应可能存在很大差异。本文综述了 HCC 管理的最新进展，并比较了东西方 HCC 的策略。
